SCHEMBL8712013

SCHEMBL8712013

Brc1ncccc1C1OCCO1

nearest known ligand 0.37

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.37
TRIM33 Q9UPN9 1/20 0.37
NSD2 O96028 1/20 0.30
CASP6 P55212 1/20 0.30
CYP11B1 P15538 1/20 0.30
CYP11B2 P19099 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30749231 1.00 TRIM24 (0.37) TRIM24TRIM33NSD2CASP6CYP11B1
SCHEMBL9542666 0.77 NPC1 (0.39)
SCHEMBL170059 0.77 NAPRT (0.36)
SCHEMBL28546297 0.74 TRIM24 (0.35) TRIM24TRIM33
SCHEMBL28036738 0.74 PDK2 (0.46) TRIM24TRIM33CYP11B1CYP11B2
SCHEMBL17796068 0.73 NSD2 (0.36) NSD2CASP6
SCHEMBL24417412 0.73 CYP11B1 (0.35) CYP11B1CYP11B2
SCHEMBL21505570 0.73 TRIM24 (0.34) TRIM24TRIM33
SCHEMBL26123737 0.73 GAA (0.33) NSD2CASP6
SCHEMBL5347558 0.72 DRD2 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4573096-A1 INHIBITORS OF MYELOPEROXIDASE Astrazeneca AB (SE) 2025-06-25 EP disclosed
US-20240166642-A1 INHIBITORS OF MYELOPEROXIDASE ASTRAZENECA AB (SE) 2024-05-23 US disclosed
WO-2024038131-A1 INHIBITORS OF MYELOPEROXIDASE ASTRAZENECA AB (SE) 2024-02-22 WO disclosed
EP-3782995-B1 SPIRO CONDENSED IMIDAZOLINE-2,4-DIONE DERIVATIVES AS HISTONE ACETYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES SHANGHAI INST MATERIA MEDICA CAS (CN) 2023-11-22 EP disclosed
EP-3782995-A1 HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) 2021-02-24 EP disclosed
WO-2019201291-A1 HISTONE ACETYLTRANSFERASE (HAT) INHIBITOR AND USE THEREOF 中国科学院上海药物研究所 2019-10-24 WO disclosed
US-5716971-A FOR TREATMENT OF ANGINA PECTORIS AND HYPERTENSION TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-02-10 US disclosed
EP-0623597-B1 Pyridine derivatives, with potassium channel opening activity TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1997-10-22 EP disclosed
CN-1097741-A Pyridine derivate, Preparation Method And The Use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 1995-01-25 CN disclosed
EP-0623597-A1 Pyridine derivatives, with potassium channel opening activity Takeda Chemical Industries, Ltd. (JP) 1994-11-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240166642-A1 INHIBITORS OF MYELOPEROXIDASE MPO, XDH, EPX TRIM24 3690/4885TRIM33 3145/4885NSD2 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.